Type 2 Diabetes Mellitus Completed Phase 2 Trials for Empagliflozin (DB09038)

Also known as: Diabetes Mellitus Non-insulin-dependent / Type-2 Diabetes Mellitus / Diabetes Mellitus Type 2 (T2DM) / Diabetes Mellitus Type-2 / Type 2 Diabetes (T2DM) / Diabetes, Type 2 / Diabetes Mellitus, Type 2 (T2DM) / Diabetes Mellitus´╝îType 2 / Diabetes Type II / Type-II Diabetes Mellitus / Diabetes Mellitus 2 Type / T2DM / Diabetes Mellitus Type II / Type II Diabetes / Diabetes Mellitus, Type 2 / Type 2 Diabetes Mellitus (T2DM) / Diabetes Type Two / Diabetes Mellitus - Type 2 / Diabetes, Type II / Non-Insulin-Dependent Diabetes Mellitus / Diabetes Mellitus. Type 2 / Diabetes Type 2 / Type 2 Diabetes Mellitus (T2D) / Type 2 Diabetes (T2D) / Type II; Diabetes / Type II Diabetes Mellitus / Diabetes Mellitus, Type II / NIDDM / Type-2 Diabetes / Type 2 Diabetes Mellitus(T2DM) / Type 2 Diabetes / Type 2-diabetes / Noninsulin Dependent Diabetes Mellitus, Type II / Diabetes Mellitus Type 2 / Type Two Diabetes Mellitus / T2DM (Type 2 Diabetes Mellitus) / Type-2-diabetes Mellitus / Diabetes mellitus -adult onset / Diabetes mellitus non insulin-dep / Maturity onset diabetes / Diabetes mellitus maturity onset

IndicationStatusPhase
DBCOND0029752 (Type 2 Diabetes Mellitus)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02632747Empagliflozin and ACEi- Effects on Hyperfiltration: BETWEEN StudyTreatment
NCT01867307Effect of Empagliflozin Kinetics on Renal Glucose Reabsorption in Patients With Type II Diabetes and Healthy ControlsTreatment
NCT01248364A Study to Determine Acute (After First Dose) and Chronic (After 28 Days) Effects of Empagliflozin (BI 10773) on Pre and Postprandial Glucose Homeostasis in Patients With Impaired Glucose Tolerance and Type 2 Diabetes Mellitus and Healthy SubjectsTreatment
NCT01193218Empagliflozin (BI 10773) Dose Finder Study in Japanese Patients With Type 2 Diabetes MellitusTreatment
NCT01011868Efficacy and Safety of BI 10773 in Combination With Insulin in Patients With Type 2 DiabetesTreatment
NCT0078903512 Weeks Treatment With 3 Different Doses of BI 10773 in Type 2 Diabetic PatientsTreatment
NCT008851184 Weeks Treatment With Empagliflozin (BI 10773) in Japanese Type 2 Diabetic Patients (T2DM)Treatment
NCT00881530Empagliflozin (BI 10773) in Type Two Diabetes (T2D) Patients, Open Label ExtensionTreatment
NCT01649297A 16 Weeks Study on Efficacy and Safety of Two Doses of Empagliflozin (BI 10773) (Once Daily Versus Twice Daily) in Patients With Type 2 Diabetes Mellitus and Preexisting Metformin TherapyTreatment
NCT00749190BI 10773 add-on to Metformin in Patients With Type 2 DiabetesTreatment
NCT03027960Empagliflozin in Heart Failure: Diuretic and Cardio-Renal EffectsTreatment